A team of researchers at NYU Abu Dhabi (NYUAD), led by Khalil Ramadi, assistant professor of bioengineering at NYU Tandon and director of the Institute for Advanced Neuroengineering and Translational Medicine at NYU Abu Dhabi, is conducting a first-ever gastrointestinal and A class of ingestible electrical devices for neuromodulation of the gut-brain axis, a signaling pathway between the central nervous system. Ingestible capsules are a non-invasive and precise method that can be used to regulate hunger levels and treat metabolic and neurological disorders. and MIT graduate student James McRae, the original co-author of a paper published in the journal Science Robotics.
The FLASH system uses electrodes on its surface to electrically stimulate the mucosal tissue of the stomach. The gut-brain axis regulates several physiological functions, including feeding and emotional behavior. Existing pharmaceutical and surgical methods for adjusting the axis, including surgical electrode implantation, are imprecise, invasive, and associated with significant recovery periods and associated risks. Inspired by the water-absorbing skin of Moloch horridus, an Australian spiny devil lizard, FLASH features a liquid-wicking capsule coating with a grooved pattern and a hydrophilic (water-compatible) surface that allows the skin to absorb into the stomach. A direct electrode is achieved by bypassing the gastric juice. -Tissue contact.
Gastric electrical stimulation (GES) directly induces the release of ghrelin, a hormone that stimulates hunger, from the gastric mucosa through endoscopic stimulation. Oral ingestion of FLASH capsules was shown to significantly and repeatedly modulate ghrelin hormone levels. In a paper published today titled Bioinspired, Liquid Wicking, Ingestible Electroceutical Capsules for Hunger-Regulating Hormone Regulation, the researchers found that the It reports the development process of his FLASH capsule. Capsules were shown to be powered by an ingestible battery, stimulated for 20 minutes, and excreted within 2 weeks of ingestion by large animals.
Current hormonal agents have poor bioavailability when taken orally. Therefore, it is necessary to inject drugs such as insulin. FLASH specifically targets the gastric neurohormonal circuit and can be taken orally to regulate hormone levels in the blood. We anticipate that this device could be used in a variety of applications to treat metabolic, feeding, gastrointestinal and neuropsychiatric disorders non-invasively and with minimal off-target effects.
“Electroceuticals, or electrostimulation therapy, is emerging as the next frontier in neuromodulation,” Ramadi said. “FLASH is one of the first ingestible electroceuticals that can modulate precise neurohormonal circuits while avoiding the discomfort patients experience with invasive treatments. Future ingestible electroceutical systems are , may be designed and customized for specific applications beyond acute short-term gastric irritation.”
Original: Researchers at NYU Abu Dhabi have developed the first-ever ingestible electroceutical device that controls appetite through hormonal regulation
Than: New York University Abu Dhabi | Massachusetts Institute of Technology
